Dupixent Lawsuit

Were  you diagnosed with Cutaneous T-cell Lymphoma (CTCL)Mycosis fungoides, or Sezary syndrome, after taking the biologic medication Dupixent?

Fill out the form and get a free case evaluation today!

You may be eligible for compensation image description
image description

Dupixent Cutaneous T-cell Lymphoma (CTCL) Attorneys

Seeger Weiss is investigating claims of Cutaneous T-cell Lymphoma diagnoses in people who took the biologic medication Dupixent for inflammatory disorders.

Dupixent May Increase the Risk for Certain Lymphoma Cancers

You may be eligible for compensation
Dupixent lawsuit

Dupixent (dupilumab) is an injectable biologic medication used to treat certain types of inflammatory diseases. It works by treating the underlying cause of inflammation and is commonly prescribed for people with atopic dermatitis, eczema, asthma, chronic sinusitis, and eosinophilic esophagitis.

Recent studies have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication. People who used Dupixent and were later diagnosed with CTCL may be eligible for compensation.

Dupixent Cutaneous T-cell Lymphoma Cancer Risk

As part of the immune system, skin plays a major role in the lymphatic system. Certain cancers of the lymph system are known as Lymphomas.

Cutaneous T-cell Lymphoma is a type of cancer that originates in the skin. It is one of the non-Hodgkins Lymphoma group of cancers that affects a certain type of white blood cell known as T-cells.

CTCL may include subtypes of Cutaneous T-cell Lymphoma including Sezary Syndrome, Mycosis Fungoides, and other T-cell Lymphoma subtypes.

Symptoms of CTCL may include:
  • Itching
  • Red, scaly, or thickened patches of skin
  • Peeling skin
  • Discolored skin
  • Raised bumps or nodules
  • Skin sores or ulcers
  • Hair loss
  • Enlarged lymph nodes

Recently published studies showed that Dupixent may increase the risk of development of CTCL by 300% or more. In some cases, Dupixent may have hidden undetected CTCL when it was used to treat conditions with similar symptoms to cancer or may have worsened existing conditions. Drug manufacturers may have known about the risks of their medications and failed to warn patients and the medical community.

People who took Dupixent for conditions such as eczema, atopic dermatitis, or other conditions and later developed Cutaneous T-cell Lymphoma (CTCL), Sezary Syndrome, or Mycosis Fungoides may be eligible for compensation.

Sources:

Cutaneous T-cell Lymphoma, Cleveland Clinic (09/2025)

Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study, JAAD (08/2024)

Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis, Dermatologic Therapy (08/2024)

Cutaneous T-cell lymphoma following dupilumab use: a systematic review, International Journal of Dermatology (09/2022)

You may be eligible for compensation
Awards

Recognized for excellence

No aspect of this advertisement has been approved by the Supreme Court of New Jersey.

Best lawyers 2026

In the 2026 edition of Best Law Firms, ranked by Best Lawyers, Seeger Weiss was recognized nationally for the firm’s representation of plaintiffs in mass tort and class action litigation. Best Law Firms is issued by Best Lawyers.

Learn more about their selection methodology

For the fifth consecutive year, Chambers honored Seeger Weiss with the highest firm recognition, Band 1, in the 2025 Chambers USA Product Liability: Plaintiffs guide. Partners Chris Seeger, Dave Buchanan, Ben Barnett & Parvin Aminolroaya were also featured in the guide. These recognitions are issued by Chambers and Partners.

Learn more about their selection methodology

Seeger Weiss was recognized as Products Liability Practice Group of the Year at The National Law Journal’s 2025 Elite Trial Lawyers award ceremony. The 2025 Products Liability Practice Group of the Year award is issued by The National Law Journal.

Learn more about their selection methodology
l image

Law360 selected Seeger Weiss’s product liability practice as a 2023 Practice Group of the Year. The award honors “attorney teams behind litigation wins and major deals that resonated throughout the legal industry this past year.” This award is issued by Law360.

Learn more about their selection methodology
Testimonials

What people have to say about us

The settlement has significantly impacted my life and future financial security. It will allow me to maintain and enjoy my quality of life in my new home near my daughter for an extended time.

Linda J.

I am so very thankful to the Seeger Weiss law firm for their dedication and support …

Bernard S.

Seeger Weiss made sure I was taken care of.

Keith M.

They treated me not as a client, but as family.

Debbie D.
Results may vary depending on your particular facts and legal circumstances.
Faq

Frequently Asked Questions

  • About Seeger Weiss

    Seeger Weiss is best known for multidistrict mass torts and class actions in both state and federal court. From offices in New York, New Jersey, and Pennsylvania, and Massachusetts, the firm has represented over 10,000 individuals, companies, and governments across the U.S. who have been injured or defrauded on a massive scale.

    Since its founding in 1999, it has led many of the most complex and high-profile cases in the country: the National Prescription Opiate Litigation; 3M Combat Arms Earplug Products Liability Litigation; the ongoing “Dieselgate” scandal; the sprawling multistate litigation on behalf of survivors of child sexual abuse; and the Football League Players’ Concussion Injury Litigation.

    Seeger Weiss doesn’t simply “collect” clients for other lawyers to serve. We go to court and get results, having achieved multiple recoveries in the hundreds of millions and billions of dollars on behalf of large classes of injured clients. Whatever the case, we have the experience and resources necessary to go toe-to-toe with the biggest and best-funded corporations in America.

    Prior results do not guarantee or predict a similar outcome in any future matter.

  • Who am I talking to when I call Seeger Weiss?

    Almost of our calls are initially handled by our talented reception team. Depending on the nature of the call, they may connect you to one of Seeger Weiss’s intake specialists (for prospective clients) or to one of our case management paralegals (for current clients). These teams are here to answer your questions, provide context, and help guide you through process of becoming a client or of pursuing your case in court.

  • Do I have to pay?

    The vast majority of the work Seeger Weiss does is on a contingency basis. That means we are paid only once we have secured financial compensation via trial or settlement—usually a percentage of the total award. Individual retainer agreements, which prospective clients must review and sign to retain Seeger Weiss as their legal representation, will share information on how your contingency fee works.

  • I just signed a retainer, what happens next?

    Once you’ve signed a retainer agreement with Seeger Weiss, the firm becomes your legal representation. For the firm, our next step is to gather as much information about your case as possible. Typically, that means you’ll sign authorization forms that allow us to speak on your behalf to or obtain information from other organizations and institutions, such as a primary care physician’s office or a hospital.

Diagnosed with Cutaneous T-cell Lymphoma (CTCL),  Mycosis fungoides, or Sezary syndrome, after taking Dupixent?

Free Case Evaluation